Methods to reduce adverse events caused by pharmaceutical preparations comprising plasma derived proteins
AssigneeCSL Behring GmbH
InventorsStefan SCHULTE, Uwe KALINA, Michael MOSES, Annette FEUSSNER
Life of this patent
Estimating the term…
Abstract
The instant invention provides a method to reduce adverse events caused by a pharmaceutical preparation derived from a plasma fraction wherein the method comprises contacting the plasma fraction with heparin or a heparin-like substance thereby reducing the activity of at least one activated serine protease per ml of the plasma fraction.
Claims20
-15. (canceled)
A method of removing activated serine proteases from a plasma fraction comprising antithrombin III, wherein the method comprises adsorbing the plasma fraction to an anion exchange (AEX) matrix and contacting the matrix-adsorbed plasma fraction with heparin or a heparin-like substance, wherein the activity of at least one activated serine protease per ml of the plasma fraction is reduced.
A method of removing activated serine proteases from a plasma fraction comprising antithrombin III, wherein the method comprises contacting the plasma fraction with heparin or a heparin-like substance covalently bound to a matrix, wherein the activity of at least one activated serine protease per ml of the plasma fraction is reduced.
Dependencies are inferred from the claim text.